الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 81 |  |  |
| | | from | 81 | | |
Abstract
Psoriasis is a complex, chronic, multifactorial, inflammatory disease that involves hyperproliferation of the keratinocytes in the epidermis, with an increase in the epidermal cell turnover rate, it presents in multiple forms such as plaque, flexural, guttate, pustular or erythrodermic.
Psoriasis is a genetically inherited immune-mediated inflammatory disease that can be triggered by skin injury, stress, infection, and certain drugs.
Psoriasis is a skin condition characterized by epidermal hyperplasia and dermal immune cell infiltration. It has a complicated pathogenesis involving the interplay of immune cells, keratinocytes and other skin-resident cells. Activation of pDCs leads to maturation of mDCs and production of TNF-α, IL-12 and IL-23, which in turn activates Th 1 and Th17 and secretion of inflammatory cytokines, such as IL-17, IL-21, IL-22 and TNF-α. Activated keratinocytes by these cytokines (especially IL-17) produces antimicrobial peptides, chemokines and cytokines which contributes to the amplification of inflammation.
Psoriasis is associated with psoriatic arthritis and increased prevalence of hepatic, cardiometabolic and psychological comorbidity requires a comprehensive and multidisciplinary care approach.
Several scores are available to assess the degree of psoriasis severity as: BSA, PASI score.
Psoriasis treatments include topical agents (corticosteroids, vitamin D analogues, phototherapy (psoralen and ultraviolet A radiation (PUVA) and narrowband ultraviolet B radiation (NB-UVB)) and standard systemic therapies (ciclosporin, methotrexate, acitretin, small molecule inhibitors (apremilast) and biologic IL-17, IL-23 and TNF inhibitors.
IL-15 is a cytokine involved in both innate and adaptive immunity. Additionally acting as a growth factor and promoting the survival of T, B and NK cells by inhibiting apoptosis.
The aim of this research was to assess the levels of IL-15 in the serum of psoriatic patients.
This study was conducted on 50 patients with psoriasis and 20 healthy controls of the same age group who were selected from the dermatology outpatient clinic, Alexandria main university hospital, Alexandria University.
Any participant having concomitant inflammatory or autoimmune cutaneous or systemic diseases that could affect IL-15 serum level, pregnant or lactating was excluded from the study.
In all participants, complete medical history was taken, BSA and PASI scores were also calculated. Serum levels of IL-15 were measured by ELISA kits.
In the present study the number of patients with mild PASI score was 8/50 (16.00%), moderate was 9/50 (18.00%) and severe was 33/50 (66.00%).
Regarding sex, 66.00% of the patients were males while 34.00% of the patients were females with the age ranged from 18.00 to 68.00.
The treatment stoppage time (months) ranged from 1.00 to 72.00 with a median of 5.50.